Boston Scientific Faces Setback; Acquisition of Penumbra Expected to Boost Stock Performance.
Written by Emily J. Thompson, Senior Investment Analyst
Source: Barron's
- Acquisition Focus: Boston Scientific is heavily focused on acquisitions as part of its growth strategy.
- Stock Impact: The latest acquisition has negatively affected the company's stock in the short term, but it is expected to yield positive results in the future.
- Investor Patience: Investors are encouraged to remain patient as the long-term benefits of the acquisition are anticipated to materialize.
- Future Outlook: Despite current stock challenges, the outlook for Boston Scientific remains optimistic due to its strategic acquisitions.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 359.400
Low
266.00
Averages
344.64
High
388.00
Current: 359.400
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies
- Investor Rights Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE:PEN) regarding its sale to Boston Scientific Corporation for $374 million in cash or 3.8721 shares of Boston Scientific common stock, potentially indicating breaches of fiduciary duties to shareholders.
- RAPT Therapeutics Transaction Review: The company (NASDAQ:RAPT) is being sold to GSK plc for $58 per share, with Halper Sadeh LLC possibly seeking increased consideration and additional disclosures for shareholders.
- Lisata Therapeutics Transaction Issues: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4 per share in cash plus two non-tradeable contingent value rights, prompting Halper Sadeh LLC to assess the legality and impact of this transaction on shareholders.
- Legal Consultation Services: Halper Sadeh LLC offers free legal consultations, encouraging shareholders to reach out to discuss their rights and options, demonstrating the firm's commitment to protecting investor interests and pursuing potential legal remedies.
Continue Reading
Halper Sadeh LLC Investigates Penumbra and RAPT Transactions
- Legal Investigation Launched: Halper Sadeh LLC is investigating the transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation, involving either 3.8721 shares of Boston Scientific common stock or $374.00 in cash, potentially indicating breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm may seek increased consideration and additional disclosures for Penumbra shareholders, aiming to ensure that their legal rights are fully protected during the transaction process.
- RAPT Transaction Review: Halper Sadeh LLC is also examining the acquisition of RAPT Therapeutics, Inc. (NASDAQ: RAPT) by GSK plc at a price of $58.00 per share, which may impact shareholder interests significantly.
- Global Investor Support: Halper Sadeh LLC offers legal consultations without upfront fees, encouraging affected shareholders to reach out to discuss their rights and options, highlighting its commitment to protecting global investor interests.
Continue Reading